Physician profile
Saikrishna Gadde
NPI 1497134118
$58,121.55
in general payments reported to CMS, 2019-2025
57 companies · $29K in 2025
The $29K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $485 · 2020: $404 · 2021: $310 · 2022: $983 · 2023: $1,574 · 2024: $26K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $32K · Travel and Lodging: $11K · Food and Beverage: $5,408 · Consulting Fee: $5,325 · Honoraria: $2,450 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $31,727.50 |
| Travel and Lodging | $10,910.24 |
| Food and Beverage | $5,407.65 |
| Consulting Fee | $5,325.00 |
| Honoraria | $2,450.00 |
| Education | $118.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $43,364.57 | 2024-2025 | Cabometyx |
| Eisai INC. | $5,812.09 | 2022-2025 | |
| Taiho Oncology, INC. | $1,407.87 | 2025 | |
| Incyte Corporation | $1,271.80 | 2023-2025 | Zynyz, Jakafi, Monjuvi |
| Merck Sharp & Dohme LLC | $650.86 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $451.66 | 2020-2025 | Tagrisso, Imfinzi, Calquence |
| E.R. Squibb & Sons, L.L.C. | $385.57 | 2019-2025 | Opdivo, Opdualag |
| Pfizer INC. | $380.36 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $338.87 | 2020-2025 | |
| Amgen INC. | $261.51 | 2021-2023 | Xgeva, Vectibix, Nplate |
| Astellas Pharma US INC | $238.45 | 2022-2025 | Cresemba, Padcev, Vyloy |
| Celgene Corporation | $218.58 | 2021-2025 | Reblozyl, Pomalyst, Pomalyst |
| Aveo Pharmaceuticals, INC. | $207.07 | 2022-2025 | Fotivda |
| Daiichi Sankyo INC. | $196.73 | 2022-2025 | Enhertu, Injectafer, Vanflyta |
| Regeneron Healthcare Solutions, INC. | $195.17 | 2019-2025 | Libtayo |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $188.42 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $178.82 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $172.62 | 2021-2024 | Alunbrig, Iclusig, Fruzaqla |
| Janssen Biotech, INC. | $172.42 | 2024-2025 | Tecvayli, Erleada, Akeega |
| Genentech USA, INC. | $171.85 | 2022-2024 | Perjeta, Phesgo, Columvi |
| Gilead Sciences, INC. | $148.89 | 2022-2025 | Trodelvy |
| Glaxosmithkline, LLC. | $145.73 | 2023-2025 | Jemperli, Ojjaara |
| Pharmacyclics LLC, An Abbvie Company | $114.23 | 2019-2022 | |
| Lilly USA, LLC | $113.93 | 2022-2025 | Verzenio, Retevmo, Jaypirca |
| Emd Serono, INC. | $99.02 | 2021-2024 | Tepmetko, Bavencio |
| Deciphera Pharmaceuticals INC. | $96.60 | 2022-2025 | Qinlock, Romvimza |
| Seagen INC. | $96.33 | 2022-2023 | Tukysa, Padcev |
| Alexion Pharmaceuticals, INC. | $89.00 | 2021-2024 | Ultomiris |
| Kite Pharma, INC. | $82.63 | 2024-2025 | Yescarta |
| Abbvie INC. | $82.29 | 2022-2024 | |
| Tempus Ai, INC | $72.10 | 2024-2025 | Xt Cdx |
| Karyopharm Therapeutics INC. | $70.37 | 2022-2025 | Xpovio |
| Array Biopharma INC | $64.75 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Bayer Healthcare Pharmaceuticals INC. | $61.64 | 2022-2025 | |
| Beigene USA, INC. | $61.51 | 2023-2024 | Brukinsa |
| Sun Pharmaceutical Industries INC. | $39.41 | 2022-2023 | Odomzo, Yonsa |
| Alnylam Pharmaceuticals INC. | $32.54 | 2022-2023 | Amvuttra |
| Pharmacosmos Therapeutics INC. | $32.34 | 2023-2025 | Monoferric |
| Ipsen Biopharmaceuticals, INC | $32.09 | 2021-2022 | |
| Springworks Therapeutics, INC. | $31.70 | 2025 | Ogsiveo |
| Mirati Therapeutics, INC. | $29.35 | 2023 | Krazati |
| Tersera Therapeutics LLC | $24.58 | 2024 | Xermelo |
| Beone Medicines USA, INC. | $23.96 | 2025 | Brukinsa |
| Blueprint Medicines Corporation | $23.41 | 2025 | Ayvakit |
| Geron Corporation | $21.31 | 2025 | Rytelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.25 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $19.14 | 2025 | Sancuso |
| Sobi, INC | $18.84 | 2024 | |
| Pharming Healthcare, INC. | $18.46 | 2023 | Ruconest |
| Myriad Genetic Laboratories, INC. | $16.81 | 2024 | Myrisk |
| Syndax Pharmaceuticals, INC. | $16.36 | 2025 | |
| Caris Mpi, INC. | $16.19 | 2025 | Mi Cancer Seek |
| Rigel Pharmaceuticals, INC. | $15.34 | 2022 | |
| Foundation Medicine, INC. | $13.40 | 2021 | |
| Kyowa Kirin, INC. | $12.76 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$940.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saikrishna Gadde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.